The risk of heart attack, stroke and cardiovascular death dropped significantly in patients that took the new weight-loss drug over a five-year period.
The risk of heart attack, stroke and cardiovascular death dropped significantly in patients that took the new weight-loss drug over a five-year period.
Novo Nordisk said on Tuesday it would cut U.S. list prices for several insulin products by up to 75% next year, joining rival Eli Lilly and Co as political pressure mounts to make these